<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1426992C-4C2A-4FDE-8957-DA5511E95031"><gtr:id>1426992C-4C2A-4FDE-8957-DA5511E95031</gtr:id><gtr:name>Entasis Therapeutics</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1426992C-4C2A-4FDE-8957-DA5511E95031"><gtr:id>1426992C-4C2A-4FDE-8957-DA5511E95031</gtr:id><gtr:name>Entasis Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/DC3E968D-06C2-4F03-9987-D58301F99BC6"><gtr:id>DC3E968D-06C2-4F03-9987-D58301F99BC6</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:otherNames>Gerrard</gtr:otherNames><gtr:surname>Dowson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FM005011%2F1"><gtr:id>D1F03971-E0A9-4FCF-B302-5BAC810B3060</gtr:id><gtr:title>Enabling exploitation of novel reagents and assays (EnRgy) to target the inhibition of peptidoglycan biosynthesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/M005011/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>N/A</gtr:technicalSummary><gtr:potentialImpactText>N/A</gtr:potentialImpactText><gtr:fund><gtr:end>2016-03-13</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-03-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>150522</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Entasis Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Entasis collaboration</gtr:description><gtr:id>ABA64BA2-5B39-4BE4-9B4B-A589B5AFFD9C</gtr:id><gtr:impact>Successful award of Wellcome Trust Pathfinder award</gtr:impact><gtr:partnerContribution>Assay validation and hit characterisation insight</gtr:partnerContribution><gtr:piContribution>Biochemistry and assay development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Astra Zeneca global screening platform</gtr:description><gtr:id>5FA94076-06A6-4AF3-AF15-E523FCDBF40A</gtr:id><gtr:impact>Novel assay development and assay validation
Hit screening underway</gtr:impact><gtr:partnerContribution>Advice, knowledge transfer, training and access to high throughput screening platforms and chemical libraries</gtr:partnerContribution><gtr:piContribution>Knowledge transfer, biological insight and assay development</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC Flemming video</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BC9CC5EA-75B5-43D1-BC00-6BAFDC4FC4F0</gtr:id><gtr:impact>100000. Short film presentation linking our current MRC funded research to the groundbreaking work by alexander Flemming

to be released later this year as part of the MRC celebrations</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ANTRUK Antibiotic Research UK</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3AAA78CC-9F94-4DE0-B004-63CADE41A763</gtr:id><gtr:impact>Establishment of new charity and new fundraising campaign

regional and national media interest</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.antibioticresearch.org.uk</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University open day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>368CFB7B-1BE2-48F5-BBE3-DC84FC298ED6</gtr:id><gtr:impact>Discussion around training and careers in microbiology an biomedical science

Inspired about microbiology</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>06D66A19-38B3-4FD8-AE32-C91D370C48A5</gtr:id><gtr:impact>20 questions panel followed by open discussion around - what is a scientist

Invited to attend further activities by the schools career department</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pew Road Map for Antibiotic Discovery</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50714E6C-243C-47F3-AF0F-F944F9F917B5</gtr:id><gtr:impact>The Pew Charitable Trusts convened a multidisciplinary group of leading industry and academic experts to
identify the key scientific roadblocks to antibiotic discovery and consulted with numerous other public and
private sector stakeholders to develop a Scientific Roadmap for Antibiotic Discovery. The roadmap outlines a
concrete approach-both a scientific plan and organizational structure to support this research-that would lay a
foundation for the sustained and diversified discovery and development of new antibiotics and therapies over the
coming decades.The report's key findings show a need for:
? A targeted approach to tackle the basic scientific barriers impeding antibiotic discovery and development.
? A better understanding of how to overcome the cellular defenses of drug-resistant Gram-negative bacteria,
which cause some of the most difficult-to-treat infections.
? Generation of new chemical matter designed for antibiotic discovery.
? Tools and methodologies to evaluate promising alternatives to traditional antibiotic use.
? A framework for sharing information, expertise, and materials across the research community to foster
innovative science and spur the discovery of novel antibacterial therapies.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.pewtrusts.org/~/media/assets/2016/05/ascientificroadmapforantibioticdiscovery.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Trustee for a regional science charity  MLS</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>EC62B7D2-C333-4F52-BF50-0687193D811D</gtr:id><gtr:impact>Development and distribution of new literature

Inspired fund raising</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.charitychoice.co.uk/medical-and-life-sciences-research-fund-25719</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>O'Neil AMR review</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>81CE3E78-62E1-4655-AAC7-EB60D5C527C9</gtr:id><gtr:impact>In December we published our first report1
 showing that infections caused by
drug-resistant pathogens are one of the biggest health problems the world faces
today. Bacteria and other pathogens have always evolved to resist the new drugs
that modern medicine uses to combat them. But in recent years the rise in drug
resistance has been a particular worry, especially the emergence of antibioticresistant
superbugs. Unless action is taken to address this huge global issue, our
conservative estimate is that it will cost the world an additional 10 million lives
a year by 2050, more than the number of people currently dying from cancer
annually. It will also have a cumulative cost of 100 trillion USD, more than one
and a half times annual world GDP today, or roughly the equivalent to losing the
UK economy from global output every year.
We now turn our attention to how this problem can be tackled. This paper is the
first in a series that works towards global and sustainable solutions. There are
many angles to the problem that we will need more time to consider. In particular,
the focus of our next paper, due to be published in the spring, will be how to
stimulate the market for companies to invest in and develop new antimicrobials and
diagnostics, which is not fully addressed here. There we will assess potential 'push'
and 'pull' incentives to encourage the development of new antimicrobial drugs,
and set out our proposals for action by policy makers. In later papers we will also
focus on important issues such as the use of antibiotics in agriculture and potential
alternatives to antimicrobials</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>https://amr-review.org/sites/default/files/Report-52.15.pdf</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio 4 3 part drama production</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>97D14BB2-3914-4390-ADA9-30F9D08518C6</gtr:id><gtr:impact>Radio drama highlighting factors driving antibiotic resistance and global consequences - raising public awareness at the National level</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b08g7y1l</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Coventry General Charities</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>General Charity of the City of Coventry</gtr:fundingOrg><gtr:id>1FBC67FD-A43F-4254-B15E-DC8C30764DBC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC AMR theme 1 collaboration award</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5505BE61-1856-4B3A-A424-267D9E3BCBCB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Accelerate CHNUK AMR discovery: Establishing joint China/UK training and research platforms enabling highthroughput fragment based inhibitor discovery</gtr:description><gtr:end>2019-05-02</gtr:end><gtr:fundingOrg>Newton Fund</gtr:fundingOrg><gtr:fundingRef>MR/P007503/1	</gtr:fundingRef><gtr:id>D69A9609-7E96-47FE-B04B-ADE12AECAE3E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>They have informed global pharma, given them new insight and new approaches for antibiotic discovery, including the development of new screening capabilities in the form of reagents and assays</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>E01FF2A4-38D9-443A-A1BB-4367A03FF5CA</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Aerospace, Defence and Marine,Education,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Optimisation of peptidoglycan pathway intermediates synthesis and purification</gtr:description><gtr:id>260114F6-953A-410F-9C64-E72DA11F8A72</gtr:id><gtr:impact>Development of a synthesis facility to provide thes eintemediates to the global research community and the fundamental platform for several UK and international peptidoglycan networks</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Synthesis of peptidoglycan intermediates</gtr:title><gtr:yearProtectionGranted>2006</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>Knowledge transfer from the pharmaceutical antibiotic discovery industry to academia and vice versa. More effective approaches to industry</gtr:description><gtr:exploitationPathways>Additional support for academic and industrial leave and engagement</gtr:exploitationPathways><gtr:id>FA4F8711-E6E6-46A2-BC23-B8AABF7B7208</gtr:id><gtr:sectors><gtr:sector>Education,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Antimicrobial Discovery Solutions Ltd</gtr:companyName><gtr:description>Reagents, assay development and services</gtr:description><gtr:id>D4B9E8EC-8BD3-4ACF-BFD3-F84F7D5D14C6</gtr:id><gtr:impact>N/A</gtr:impact><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C183105-49ED-41C5-BF95-42CDB980A61D"><gtr:id>3C183105-49ED-41C5-BF95-42CDB980A61D</gtr:id><gtr:title>Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/570dcdda9f8064c09def9cbe6583ab32"><gtr:id>570dcdda9f8064c09def9cbe6583ab32</gtr:id><gtr:otherNames>Vajs J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A45C3F7-009B-4035-A2D8-05BF2C2CFE55"><gtr:id>0A45C3F7-009B-4035-A2D8-05BF2C2CFE55</gtr:id><gtr:title>Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e93a23805972b417db19d67fd4fe977"><gtr:id>4e93a23805972b417db19d67fd4fe977</gtr:id><gtr:otherNames>Tran AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/M005011/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>2607D197-52EE-40CA-A1D5-A46D18C3F97F</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Microbial sciences</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>18D298A9-FFE3-432F-B077-E3B703272E29</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biochemical engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>649031FD-C21E-42D9-AC12-41ACA59CC11C</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biochemistry &amp; physiology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>02567418-12CB-462E-9092-530C6E63B359</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Chemical Biology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>5BA89E2C-27FE-4553-819B-3CE27FC71EC2</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Microbiology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>